Clinical Trials Logo
  1. Home
  2. Tenosynovial Giant Cell Tumor
  3. NCT04488822

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT — PLX3397  

Tenosynovial Giant Cell Tumor Clinical Trial

Official title:
Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor

Clinical Trial Summary

This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.

Clinical Trial Description

Participants with symptomatic TGCT will be administered pexidartinib 400 mg twice daily continuously with 28-day treatment cycle until criteria for discontinuation are reached. Participants who complete primary endpoint assessments may be eligible to continue receiving pexidartinib until disease progression, unacceptable toxicity, the occurrence of other termination criteria, or withdrawal from the study. Eligible participants' status will be collected every 6 months as a long term follow-up at least 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04488822
Study type Interventional
Source Daiichi Sankyo
Contact
Status Active, not recruiting
Phase Phase 3
Start date September 25, 2020
Completion date February 28, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01207492 - Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Phase 2
Active, not recruiting NCT04938180 - A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients Phase 2
Completed NCT04526704 - Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib Phase 4
Active, not recruiting NCT05059262 - Study of Vimseltinib for Tenosynovial Giant Cell Tumor Phase 3
Active, not recruiting NCT04731675 - An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee Phase 2
Completed NCT02371369 - Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) Phase 3
Recruiting NCT04703322 - A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan Phase 2
Completed NCT02471716 - Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor Phase 1/Phase 2
Recruiting NCT04635111 - A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Recruiting NCT05349643 - A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT Phase 2
Recruiting NCT04192344 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor Phase 1
Terminated NCT02673736 - A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor Phase 1
Active, not recruiting NCT03069469 - Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Phase 1/Phase 2
Terminated NCT01804530 - Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05804045 - Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) Phase 3